KDMN News and Press, Kadmon Holdings Inc. From 09/08/21

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy PARIS, FRANCE and NEW YORK, NY / ACCESSWIRE / Sep...

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment to prescribed patients in the United States. REZUROCK was approved on July 16, 202...

Analysts Are Bullish On These Penny Stocks Finding penny stocks to buy doesn’t have to be overly complicated. Research is a big part of identifying trends and opportunities early. Sometimes analysts can be helpful in adding some insight to your DD process. In this article, we...

Kadmon (NASDAQ:KDMN): Q2 GAAP EPS of -$0.18 in-line. Revenue of $0.2M (-55.6% Y/Y) misses by $0.18M. At June 30, 2021, the Company's cash, cash equivalents and marketable debt securities totaled $270.5M, compared to $123.9M at December 31, 2020. The Company expects its current financial posit...

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patient...

Kadmon Holdings (NASDAQ:KDMN) announces that the National Comprehensive Cancer Network (NCCN) has added Rezurock tablets to its guidelines for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (G...

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network ® (NCCN) added REZUROCK TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Hematopoi...

Keros Therapeutics (KROS +3.8%) announces the appointment of Simon Cooper, M.B.B.S, as Keros' Chief Medical Officer, or CMO, effective as of August 2, 2021. Dr. Cooper most recently served as the Senior Vice President, Chief Medical Officer of Kadmon (NASDAQ:KDMN). Dr. Cooper is succeeding Cl...

Despite an approval, Kadmon hasn’t done as well as it should. The criminal pasts of its founders have been used as a way to keep it down. 2-4 quarters of solid revenues should change all that. For further details see: Kadmon: What Will Lead To A Short Squeeze

Should you buy penny stocks today ? If you like volatility, quick gains, handle high-risk situations and understand trading basics, I say, why not? But the stock market today isn’t like it was even just a year ago. The fact is, millions of new traders have flooded into the market...